TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in Quality of Life Measured Using the RAND 36-item Short Form Health Survey Physical Component Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of complications reported
Endpoint domain: Adverse events/effects
Primary endpoint: Cell-free serum hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percent weight regained
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: urinary 5-amino-imidazole-4-carboxamide (AICA) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Participants Successfully Withdrawn From Immunosuppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve (AUC) of EE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve (AUC) of LNG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Concentration (Cmax) of EE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Concentration (Cmax) of LNG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Concentration at the End of the Dosing Interval (Ctau) of EE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of IVIG-L
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of primary graft non-function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of re-transplantation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rates of recipient death
Endpoint domain: Mortality/survival
Primary endpoint: Reduction in serum phosphorus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Pain scores during rest and movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tumour size reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Antibody titers against pneumococcal serotypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Resolution of asymptomatic bacteriuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Babies With Reintubation
Endpoint domain: Adverse events/effects
Primary endpoint: NephroCheck test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Chronic stress effects on hair cortisol in picogram/milligram
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Postoperative levels of IL-6 and C-Reactive protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Ability to detect and visualize the duodenal papilla
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: General Functioning Youth
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Role and Social Functioning in Adults
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Work and Social Functioning
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Alteplase use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: all-cause morbidity
Endpoint domain: Adverse events/effects
Primary endpoint: mean vertical radiographic defect depth (VDD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent changes in peptide vaccine-specific immune responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number and severity of hematologic and nonhematologic toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Pain-free maximum mouth opening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: painDETECT
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Oral health-related quality of health
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: functional tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Isometric knee extensor strength gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anxiety at Induction of Anesthesia
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Motor Scale of the Bayley Scales of Infant and Toddler Development-III
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participants' monetary allocations
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Compensation choice
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in Activation of Patients
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in activity and participation
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Onset of labor/delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Number of Participants at Each Global Rank Endpoint Based Upon Their Most-severe Outcome
Endpoint domain: Mortality/survival
Primary endpoint: microvascular flow index (MFI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of perfused vessels (PPV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non-menstrual Pelvic Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Concentration of matrix-Gla protein and osteocalcin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Adverse events/reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Laboratory safety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of anti-JCV antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Clinician Administered PTSD Scale (CAPS) Part B and D
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Induction of photosensitization
Endpoint domain: Adverse events/effects
Primary endpoint: Modified Rankin Scale 0-1
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Hospital admission for acute exacerbation of COPD
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Safety of the exercise training
Endpoint domain: Adverse events/effects
Primary endpoint: Safety of long-term use of SA 001
Endpoint domain: Adverse events/effects
Primary endpoint: Fitbit adherence rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Satisfaction/acceptability rate questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Completion time of the star shaped manual dexterity test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC for midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: acute myocardial dysfunction (systolic and diastolic)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: dyssynchrony
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clinical relapse for CD patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical relapse for UC patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in weight during pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maternal Cytokine IL-10 Levels Upon Enrollment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Maternal Cytokine IL-10 Levels 24 Hours After Delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Umbilical Cord Cytokine IL-10 Levels at Birth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of complete excision
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Prevalence of short-term self-reported neurological symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Prevalence of short-term clinically-observed neurological symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of long-term clinically-observed neurological sequelae
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cumulative morphine consumption in 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parenting Young Children (PARYC) Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Investigator Global Assessment of Rosacea Scale Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Venous Thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Clinically Significant Improvement in Fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Clinician-rated dyskinesia severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Changes in Health Related Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of patients reaching LDL goal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Graft dislocation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: target vessel stroke event
Endpoint domain: Mortality/survival
Primary endpoint: Changes in 6 minute walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Behavioral performance during cognitive tasks
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: changes in the 17-item Hamilton Depression Rating Scale (HAMD-17)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Severity of PCS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of bolus required
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: liver-related morbidity development
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: liver-related mortality development
Endpoint domain: Mortality/survival
Primary endpoint: hepatocellular carcinoma (HCC) development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Diagnosis of occult cardiac amyloidosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: All-cause Death or Subsequent Non-fatal MI
Endpoint domain: Mortality/survival
Primary endpoint: Protection Indexes for symptomatic COVID-19
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Changes in Cerebral blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in the middle meningeal artery (MMA), superficial temporal artery (STA) and middle cerebral artery (MCA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: HSV Shedding Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Analog scale for pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute change in brain-derived blood and saliva biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute change in ocular-motor function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time to First Intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Average Bristol Stool Form Scale (BSFS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Current stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Average stress intensity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: tolerance of TPN use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease response measured by M protein quantitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of plasma cell infiltration in bone marrow biopsies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RAAS dysregulation levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical benefit of RAAS inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of involuntary commitment
Endpoint domain: Adverse events/effects
Primary endpoint: Perceived coercion
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Conversion rate for robotic surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Changes in haemodynamics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in methacholine PC20
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: side-to-side difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total anteroposterior (AP) laxity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pivot shift
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: isokinetic muscle strength evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulmonary aeration measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Upper eyelid scleral show and marginal reflex distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in depressed mood scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Life span of cultured Red Blood Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Overall Survival (OS) During the Study
Endpoint domain: Mortality/survival
Primary endpoint: Normalized summed pain intensity difference (SPID)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability to culture olfactory ensheathing cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Bacterial Microflora on the Abdomen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Clinical Depression Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Knowledge, attitude and practice mean score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Exercise engagement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Balance performance - one leg stand
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood oxygenation level dependent (BOLD) responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spine kinematics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Proprioceptive repositioning errors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Side Effects (Claim-based Measure)
Endpoint domain: Adverse events/effects
Primary endpoint: Disease-Free Survival Times
Endpoint domain: Mortality/survival
Primary endpoint: Number of participants with Treatment-emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with Dose-limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Atherosclerotic Cardio-cerebrovascular Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Freedom From Death at 30-days and 12-months Post-Index Procedure
Endpoint domain: Mortality/survival
Primary endpoint: Primary Target Lesion Patency (TLP) at Time of Procedure and 12-Months Post-Index Procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Liver cell failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Portal hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Revealing internal structure of kidney stones
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in ADAS-cog scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in CDR-SB scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of subjects with improvement in AIS grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal complications during pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Existential quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in blood brain barrier permeability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pain as side effects of the drugs
Endpoint domain: Adverse events/effects
Primary endpoint: Allergic reaction severity
Endpoint domain: Adverse events/effects
Primary endpoint: Change in frequency of regulatory B cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Recommended Phase 2 Dose (RP2D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: 7-day Point Prevalence Smoking Abstinence at 8 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 7-day Point Prevalence Smoking Abstinence at 16 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of alignment of teeth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of severe sepsis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Exercise-induced Cartilage Turnover via CTX-II Biomarker
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Combined score of erythema, infiltration and squamation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Cell profiling in acute leukemia/myeloproliferative/myelodysplastic syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cell morphology and protein expression of breast epithelial cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Methylation status of genes related to neoplastic progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Protein profile of nipple aspiration fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum protein CA9 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mRNA CA9 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ECV value change in CMR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in contrast sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Matrix Metalloproteinases (MMPs) 2 and 9 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tissue Inhibitor Metalloproteinase (TIMPs) 1 and 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Office Systolic Blood pressure change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Office Diastolic Blood pressure change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ambulatory Systolic Blood pressure change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ambulatory Diastolic Blood pressure change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: HOMA: Homeostasis Model Assessment change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: QUICKI: Quantitative insulin sensitivity check index change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Probability of Acute Graft Versus Host Disease (GVHD)
Endpoint domain: Adverse events/effects
Primary endpoint: Oxidative Phosphorylation Capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression level of NFKB Inducing Kinase (NIK)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change From Baseline in Inflammatory Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percent Change From Baseline in Non-inflammatory Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes